After the as-received Xiakang Granules Veterinary Grade API is deagglomerated through a 1.0 mm square mesh cone mill at 1,200 rpm, a dry granulation route is selected when the API presents a Hausner ratio above 1.45 and a Carr index above 28%. Direct compression is only viable when the API powder blend has a flow function coefficient above 4.0 and the API loading remains below 15% w/w. In low-dose veterinary tablets, Xiakang Granules Veterinary Grade API is typically incorporated at 8–25% w/w; high-dose formulations may reach 35–55% w/w. The milled API is blended with lactose monohydrate 200M and microcrystalline cellulose PH102 in a 600 L twin-shell V-blender operated at 12 rpm for 20 minutes. Crospovidone at 3.0% w/w is added after the first blending phase to preserve disintegrant distribution. Magnesium stearate is added in the final 2 minutes and is limited to 0.5% w/w because higher lubricant levels reduce tablet tensile strength and create hydrophobic dissolution barriers. The pre-blend is compacted on a roller compactor with 100 mm rolls, a roll gap of 0.8 mm, and a hydraulic pressure of 55 bar. The compacted ribbons are milled through a 0.8 mm grate to produce granules with a bulk density of 0.55–0.65 g/mL. Tablets are compressed on a 16-station rotary press with D tooling, using 6 kN pre-compression and 12–18 kN main compression force. Target hardness is maintained at 70–90 N and measured according to Ph. Eur. 2.9.8. Content uniformity is evaluated under USP <905>; an acceptance value below 12 is required before commercial scale-up. Disintegration is tested in 900 mL water at 37°C and should not exceed 15 minutes. Final tablets are 8 mm round, flat-faced with bevel edges, and packaged in aluminium-aluminium blister cavities. If the incoming API lot has moisture above 2.0%, it is pre-dried at 40°C under 30% RH before milling. The manufacturing area must be conditioned to 45–50% RH because dry granulation of hygroscopic veterinary APIs at higher humidity leads to ribbon adhesion and inconsistent granule size.

For tablet formulations, the release control includes assay, content uniformity, dissolution, and degradation products. Dissolution of immediate-release veterinary tablets of Xiakang Granules Veterinary Grade API is run using USP <711> Apparatus II at 50 rpm in 900 mL of 0.1 M hydrochloric acid or water, depending on the registered protocol. A rapid wet-granulation alternative is used only when the API is stable under moisture and heat. In that route, 5% w/w povidone K30 solution is sprayed into a high-shear granulator; the wet mass is dried in a fluid bed dryer at 50°C inlet air until loss on drying is below 2.0%. Dry granulation remains preferred because it avoids a drying endpoint that may shift during scale-up from pilot to production. Batch records follow 21 CFR 211.84 for component testing and 21 CFR 211.101 for charge-in verification. Sieve analysis of the compressed granules is controlled by Ph. Eur. 2.9.12; the target granule fraction between 0.180 mm and 0.850 mm should exceed 80%. If fines below 0.125 mm exceed 15%, segregation increases and content uniformity may fail on long filling campaigns. Published data for this specific API configuration is limited; a three-lot pilot study should therefore establish the correlation between roller compaction pressure and tablet dissolution before full-scale registration.

What Limits Terminal Sterilization Cycles for Injectable Veterinary APIs?

In terminal saturation sterilization of injectable veterinary formulations, the limiting parameter is the Arrhenius degradation rate of Xiakang Granules Veterinary Grade API in the selected aqueous buffer. A 20 L jacketed stainless 316L compounding vessel is charged with Water for Injection at 35°C. The API is dissolved at 1.0–10.0% w/v under low-shear agitation at 150 rpm. Sodium chloride is added to adjust osmolality to 280–320 mOsm/kg. The pH is adjusted to 5.5–7.5 with 0.1 M hydrochloric acid or sodium hydroxide. If forced degradation data show a remaining assay below 95% after 15 minutes at 121°C, terminal sterilization is rejected in favour of aseptic filtration. Aseptic filtration uses two 0.22 µm polyethersulfone cartridges in series inside an ISO 14644-1:2015 Class 5 filling isolator. The filled vials are 50 mL amber type I glass with chlorobutyl rubber stoppers. Overkill terminal sterilization, when selected, requires an F0 of at least 12 minutes. Nitrogen overlay at 0.2 bar is maintained during dissolution and filling to limit oxidative degradation. Benzyl alcohol at 1.5% v/v may be included in multi-dose cattle products, but it is not used in feline products because of benzyl alcohol toxicity. Endotoxin is tested by USP <85> with a limit of 0.5 EU/mg of API. Sub-visible particulate matter is tested by USP <788> Method 1; no more than 25 particles/mL of size ≥10 µm and no more than 3 particles/mL of size ≥25 µm may be present. Sterility is verified according to USP <71> and Ph. Eur. 2.6.1.

Steam sterilization is used only when the formulation contains a chelating agent to prevent metal-catalysed degradation. If the API contains a primary amine, reducing sugars cannot be used as tonicity modifiers because Maillard degradation forms conjugated imines that reduce assay and discolour the solution. Polysorbate 80, if required for poorly soluble veterinary APIs, is added at 0.05–0.2% w/v but must be tested for peroxide contamination before batch manufacture. The bulk solution before filtration is tested for bioburden, but final container endotoxin and sterility remain release tests. If terminal sterilization is rejected, the entire filling train must be validated with media fills at 5,000 units or greater. The holding time between bulk solution preparation and sterile filtration should not exceed 24 hours at 2–8°C unless the solution is preserved. For large-volume injectables, polyvinyl chloride infusion bags are avoided unless sorption studies show no API loss over 24 hours. Published data for the specific Xiakang Granules Veterinary Grade API configuration is limited; therefore, a forced degradation study under VICH GL18(R2) is required to justify the registered shelf-life and storage condition.

For low-dose capsule filling with Xiakang Granules Veterinary Grade API, the primary control point is powder cohesion rather than chemical assay. The as-received granules are milled through a 0.6 mm conical screen at 1,000 rpm under conditioned air at 30% RH. The milled API is blended with pregelatinized maize starch and microcrystalline cellulose PH102 in an 800 L bin blender at 10 rpm for 25 minutes. API loading between 8% w/w and 30% w/w is typical for veterinary capsules filled to 100–300 mg net fill weight. Crospovidone at 2–4% w/w is added as disintegrant. Sodium stearyl fumarate at 0.5% w/w replaces magnesium stearate when the API is acid-labile, because residual alkaline soap from magnesium stearate can accelerate degradation. The final blend is controlled to a bulk density of 0.55–0.65 g/mL and a tapped density of 0.70–0.80 g/mL. A Hausner ratio below 1.30 is required for dosator-type capsule machines. A Bosch GKF 1500 with tamping stations is set to a fill weight of 250 mg ± 5 mg. Hard gelatin capsule shells size 1 are conditioned at 20°C and 35% RH for 24 hours before filling. In-process weight checks every 15 minutes use a 20-capsule composite sample. Content uniformity follows USP <905>; the acceptance value should not exceed 15. Dissolution is performed in 900 mL of 0.1 M hydrochloric acid using USP <711> Apparatus II at 50 rpm. Terminal capsules are sealed with a gelatine band to reduce oxygen ingress. Storage above 25°C and 60% RH is not recommended because capsule cross-linking can delay dissolution. If the API is hygroscopic, a desiccant sachet is inserted and the bottle is induction-sealed before labelling.

In capsule filling, the moisture content of the powder blend is held below 4.0% because water migration into the shell causes brittleness at low humidity and tackiness at high humidity. The empty shell moisture is checked by loss on drying at 105°C until constant weight. If the API has a bitter taste, a granulation barrier is applied before capsule filling, but this must not alter dissolution by more than 5% compared with the uncoated blend. Formulation development includes a three-batch validation using Ph. Eur. 2.9.40 for uniformity of content in single-dose preparations. The semi-automatic capsule line is equipped with a metal detector and a checkweigher rejecting capsules outside ± 5 mg. Any rework of rejected capsules is prohibited because opening and recombining hard gelatin shells increases risk of split fill and loss of integrity.

Oral Powder Blend Segregation and Moisture Uptake in High-Humidity Feedlines

To prevent segregation in oral powder blends of Xiakang Granules Veterinary Grade API, a two-stage dilution is adopted rather than direct addition of active granules to a large-volume carrier. The first stage blends the milled API with anhydrous lactose monohydrate and colloidal anhydrous silica in a 500 L ribbon mixer at 20 rpm for 15 minutes. The API loading is set between 1.0% w/w and 10.0% w/w depending on the target dose per 2.5 g sachet. Colloidal anhydrous silica at 0.5–1.0% w/w reduces cohesive attraction and improves powder flow. The blending endpoint is determined by near-infrared spectroscopy after 10, 12, and 15 minutes; the endpoint is accepted when the active peak relative standard deviation is below 3%. Particle size ratio between the API and the carrier is maintained below 1.4 to limit fluidization segregation. Vibratory transfer lines longer than 5 m are avoided because repeated acceleration cycles concentrate fines at the top of the powder bed. Final moisture content is measured by Karl Fischer titration at 80°C; limits of 2.0–5.0% w/w are applied according to the product specification. Filling is performed on a horizontal form-fill-seal machine with laminate foil at 2.5 g, 10 g, and 50 g sachet sizes. Each sachet is flushed with nitrogen before sealing. The finished oral powder is labelled for distribution through a 1:100 proportioner or for direct top-dress feeding. Sieve analysis according to Ph. Eur. 2.9.12 is used for release; less than 5% of the powder may pass through a 75 µm screen if dusting is a concern. Production areas at relative humidity above 60% require dehumidification to 45% RH, because static charging accelerates segregation and water adsorption increases particle adhesion. If the API is bitter, dried brewer’s yeast at 5% w/w can be added as a palatability masking agent, but only after a compatibility screen against the active assay.

Oral powders intended for in-feed use are tested for uniformity of mass and assay before release. For sachet filling, the fill weight relative standard deviation should remain below 2% across 20 consecutive sachets. Bulk density is measured by USP <616> Method I and is reported as part of the product dossier. If the API is light-sensitive, the foil laminate must have a light transmission below 5% at 450 nm. Stability of the oral powder is assessed at 25°C/60% RH and 40°C/75% RH according to VICH GL18(R2). Any significant increase in related substances at the higher condition requires a lower registered storage temperature. The reverse blending method is used when the API loading is below 1.0% w/w, because direct blending at low active concentration can lead to high dosage unit variability.

When Premix Potency Requires a 5% Carrier Overage

When a 5% carrier overage is required for medicated premix batches, the mixing sequence is adjusted only after assay losses are identified in at least two consecutive pilot lots. A 1,000 kg horizontal double-ribbon mixer with a 3:1 length-to-diameter ratio is operated at 18 rpm for 10 minutes. The carrier is rice hulls, ground limestone, or wheat middlings with a tapped density between 0.45 g/mL and 0.60 g/mL. Xiakang Granules Veterinary Grade API is first milled through a 0.75 mm screen and combined with a conditioned carrier in a 1:9 ratio to form a 10% w/w intermediate premix. The intermediate blend is passed through a 500 µm screen to break agglomerates. This intermediate is then diluted 1:10 with carrier to produce a 1% w/w final premix. Mixer uniformity is validated by sampling 10 points, including dead zones near the discharge gate. The coefficient of variation for the active assay must be below 5%. The final premix is packed in 20 kg multiply paper bags with polyethylene liners. Inclusion rates in finished feed are calculated to deliver 1–20 mg active per kg of complete feed. 21 CFR 225.142 is applied for equipment cleanout between incompatible medicated feed batches. If the API is light-sensitive, the finished feed should not be stored in direct sunlight beyond 72 hours. Dust control is achieved by adding 0.2% w/w mineral oil or by using a counterflow dust extraction system.

Medicated premix production requires a dedicated discharge chute to prevent cross-contamination with other active ingredients. The ribbon mixer is validated with a marker tracer such as riboflavin at 0.02% w/w; visual uniformity after 10 minutes is compared with the active assay coefficient of variation. Moisture in the final premix is controlled below 6% w/w to prevent microbial growth. If the carrier has high dusting potential, a small quantity of edible mineral oil is included before the API addition. The premix is not labelled for direct oral use; it must be incorporated into complete feed by a licensed medicated feed mill. Assay of the final feed is performed after 24 hours of storage because continued mixing during transport can reduce active concentration near the feeder. For APIs with a narrow therapeutic window, the 5% overage is not used unless a bioavailability study confirms feed carryover does not exceed the withdrawal period tolerance.

Before Xiakang Granules Veterinary Grade API is dissolved in chlorinated municipal drinking water, chlorine neutralization with sodium thiosulfate is completed because free chlorine at 1–3 mg/L can form chlorinated derivatives with many veterinary actives. Sodium thiosulfate at 50–100 mg/L is added to the bulk tank before introduction of the API. The water is buffered to pH 4.5–6.0 with citric acid monohydrate at 0.2–0.5% w/v because solubility of weak bases can decline by more than 50% at pH above 7.0. A 500 L vertical high-density polyethylene tank with a bottom conical outlet is used. A low-shear marine impeller runs at 200 rpm for 10 minutes to avoid foam formation. The stock solution is prepared at 1:100 concentration and is further diluted through a dosing pump at 1:100 into the drinking water line. Final drinking water concentration is typically 5–50 mg/L depending on species and body weight. The solution is protected from light by opaque tank walls and black polyethylene pipe. If the tank is outdoors, the water temperature should not exceed 30°C for more than 24 hours. Recovery samples are drawn from drinker outlets at three points and assayed by HPLC. A stability-indicating method validated under VICH GL1 is required. Solutions without preservative should be consumed within 24 hours in warm conditions; solutions with 0.1% sodium benzoate may be held for 48 hours if the pH is below 5.5. Hard water with calcium carbonate above 200 mg/L can form insoluble salts; ethylenediaminetetraacetic acid disodium at 0.05% w/v is added only after lab-scale compatibility testing. The terminal product is medicated drinking water delivered through nipple drinkers or pan waterers.

Drinking water solution stability is evaluated at the concentration delivered in the pen, not only in the stock solution. Water samples are collected at the inlet and the end of the drinker line. Assay difference between the two points should remain below 5%. Sunlight exposure of the drinking water line is minimized by buried or black polyethylene pipe; clear polyvinyl chloride pipe is not used for light-sensitive APIs. Chlorine concentrations in the source water are checked daily and recorded before sodium thiosulfate addition. If iron or manganese exceeds 0.3 mg/L, metal-catalysed degradation may reduce the active concentration within 12 hours. In those cases, citric acid is preferred over phosphate buffers because phosphate can precipitate with hardness ions. The mixing tank is cleaned daily with 0.1% w/w sodium hydroxide and rinsed with potable water to prevent biofilm formation. A final rinse pH of 6.0–7.0 is confirmed before the next batch.

Setting Dry Granulation Parameters for Reblended API Fractions

In final oral granular dosage forms of Xiakang Granules Veterinary Grade API, bulk density and particle size are more critical than chemical assay alone because volumetric dosing devices rely on consistent granule packing. Dry granulation is selected over wet granulation when the API is moisture-labile or when residual water above 2.0% changes dissolution. A roller compactor with 120 mm rolls and a roll gap of 0.5–1.2 mm is operated at hydraulic pressure 80–120 bar. Povidone K30 at 3.0% w/w is mixed with the API before compaction if the API ribbons are brittle and fracture excessively during milling. The compacted ribbons are milled through a 1.0 mm stainless steel screen at 1,400 rpm. The granule fraction between 0.250 mm and 1.000 mm should constitute at least 80% of the mass; fines below 0.125 mm are limited to 15%. Bulk density is adjusted to 0.50–0.65 g/mL. The granules are filled into 200 g high-density polyethylene bottles with heat-sealed aluminium foil seals and 2 g silica gel desiccant. For reconstitution, 5 g of granules are dispersed in 100 mL potable water at 25°C with stirring for 30 seconds. The suspension should pass through a 0.5 mm sieve without residue. Dissolution testing of the reconstituted suspension uses USP <711> Apparatus II at 50 rpm in 900 mL water. The finished granule product is intended for oral use in swine, poultry, or companion animals. Stability of granule size distribution is monitored at 25°C/60% RH for 12 months. If the API has a narrow therapeutic window, the granule fill weight must be checked by 100% net weight control because density variation can lead to dose deviation. Published data for this specific configuration is limited; therefore, a pilot-scale densification study is required for each incoming lot of Xiakang Granules Veterinary Grade API.

Granule hardness is not directly measured on a compendial hardness tester; instead, friability under USP <1343> or a rotating screw feeder simulation is used to predict breakage. If more than 5% w/w of the granules fail to retain the original size after 10 minutes in a rotary drum, the compaction pressure is increased in 5-bar increments until the friability limit is met. Reblended API fractions are sampled at the beginning, middle, and end of the compaction run. The three samples must not differ in bulk density by more than 3%. Granule moisture is measured by Karl Fischer titration and must remain below 2.0% for the dry granulation route. If the API is electrostatic, 0.3% w/w colloidal anhydrous silica is added after compaction to reduce surface charge without changing the dissolution profile. The final granular dosage form is not milled after final blending because this can create new fines and invalidate the validated particle-size distribution. Terminal packaging is completed in a conditioned room at 20–25°C and 35–45% RH. The bottle is labelled with a withdrawal period statement and a direction to mix with drinking water or feed according to the registered species dose.